Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
19 Juli 2023 - 2:30PM
Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a
clinical-stage rare disease biopharmaceutical company developing
novel therapeutics for the treatment of pathologic mineralization
and intimal proliferation, today announced that it will host a
conference call to provide an update on the Company’s ENPP1
Deficiency program on July 26, 2023, at 8am ET.
During the call, members of Inozyme management will provide an
overview of the Company’s global development strategy for INZ-701
in patients with ENPP1 Deficiency, including the advancement of
INZ-701 in infants and design of the planned pivotal trial in
pediatric patients. Management will also highlight the market
opportunity and ongoing patient identification efforts.
The live webcast will be accessible through the Investor
Relations section of Inozyme’s website under News &
Events. To access the live call by phone, dial 1-877-270-2148
(domestic) or 1-412-902-6510 (international) and ask to be
connected to the Inozyme Pharma call. For those
unable to participate live, a replay will be available in the
Investor Relations section of Inozyme’s website for a limited
time following the event.
About ENPP1 Deficiency
ENPP1 Deficiency is a progressive condition that manifests as a
spectrum of diseases. The estimated genetic prevalence of ENPP1
Deficiency is approximately 1 in 64,000 pregnancies. Individuals
who present in utero or in infancy are typically diagnosed with
generalized arterial calcification of infancy (GACI), which is
characterized by extensive vascular calcification and intimal
proliferation (overgrowth of smooth muscle cells inside blood
vessels), resulting in myocardial infarction, stroke, or cardiac or
multiorgan failure. Approximately 50% of infants with ENPP1
Deficiency die within six months of birth. Children with ENPP1
Deficiency typically develop rickets, a condition diagnosed as
autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while
adults can develop osteomalacia (softened bones). ARHR2 and
osteomalacia lead to pain and mobility issues. Patients can also
exhibit signs and symptoms of hearing loss, arterial and joint
calcification, and cardiovascular complications. There are no
approved therapies for ENPP1 Deficiency.
About INZ-701
INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme
replacement therapy in development for the treatment of rare
disorders of the vasculature, soft tissue, and skeleton. In
preclinical studies, the experimental therapy has shown potential
to prevent pathologic mineralization and intimal proliferation (the
overgrowth of smooth muscle cells inside blood vessels), which can
drive morbidity and mortality in devastating genetic disorders such
as ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is currently in
Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and
ABCC6 Deficiency.
About Inozyme Pharma
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue,
and skeleton. We are developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in Phase 1/2 clinical trials
for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
For more information, please visit www.inozyme.com and
follow us on LinkedIn, Twitter, and Facebook.
Cautionary Note Regarding Forward-Looking
Statements
Statements in this press release about future expectations,
plans, and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to the design of our
clinical trials, the potential benefits of INZ-701 and the timing
and contents of our planned program update. The words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "will," "would," and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the
Company's ability to conduct its ongoing Phase 1/2 clinical trials
of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and
maintain necessary approvals from the FDA and other regulatory
authorities; continue to advance its product candidates in
preclinical studies and clinical trials; replicate in later
clinical trials positive results found in preclinical studies and
early-stage clinical trials of its product candidates; advance the
development of its product candidates under the timelines it
anticipates in planned and future clinical trials; obtain,
maintain, and protect intellectual property rights related to its
product candidates; manage expenses; comply with the covenants
under its outstanding loan agreement; and raise the substantial
additional capital needed to achieve its business objectives. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause the Company's actual results to
differ from those contained in the forward-looking statements, see
the "Risk Factors" section in the Company's most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission (SEC), as well as discussions of potential risks,
uncertainties, and other important factors, in the Company's most
recent filings with the SEC. In addition, the forward-looking
statements included in this press release represent the Company's
views as of the date hereof and should not be relied upon as
representing the Company's views as of any date subsequent to the
date hereof. The Company anticipates that subsequent events and
developments will cause the Company's views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Contacts
Investors:Inozyme PharmaStefan Riley, Director of IR and
Corporate Communications(857) 330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024